Eleven Biotherapeutics Inc. (EBIO) Sees Large Volume Increase
Eleven Biotherapeutics Inc. (NASDAQ:EBIO) shares saw unusually-strong trading volume on Wednesday . Approximately 5,392,432 shares traded hands during trading, an increase of 426% from the previous session’s volume of 1,024,514 shares.The stock last traded at $3.50 and had previously closed at $3.37.
The company has a 50 day moving average of $4.45 and a 200-day moving average of $2.19. The firm’s market cap is $53.88 million.
Eleven Biotherapeutics (NASDAQ:EBIO) last announced its quarterly earnings results on Friday, August 12th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter. Eleven Biotherapeutics had a negative return on equity of 207.40% and a negative net margin of 2,995.34%. Analysts predict that Eleven Biotherapeutics Inc. will post ($1.75) earnings per share for the current year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/eleven-biotherapeutics-inc-ebio-sees-large-volume-increase-2.html
In other news, major shareholder Ventures Fund 2007 L. Flagship sold 46,692 shares of the stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $4.18, for a total value of $195,172.56. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Ventures Fund 2007 L. Flagship sold 129,497 shares of the stock in a transaction dated Wednesday, September 7th. The stock was sold at an average price of $4.54, for a total transaction of $587,916.38. The disclosure for this sale can be found here. 28.70% of the stock is currently owned by insiders.
Several large investors have recently made changes to their positions in the company. Flagship Ventures Fund 2007 L.P. bought a new position in Eleven Biotherapeutics during the first quarter valued at $610,000. Flagship Ventures Fund IV L.P. bought a new position in Eleven Biotherapeutics during the first quarter valued at $469,000. Flagship Ventures Fund IV General Partner LLC bought a new position in Eleven Biotherapeutics during the second quarter valued at $2,464,000. Sabby Management LLC boosted its position in Eleven Biotherapeutics by 525.6% in the first quarter. Sabby Management LLC now owns 1,213,984 shares of the biopharmaceutical company’s stock valued at $387,000 after buying an additional 1,019,943 shares during the period. Finally, Boxer Capital LLC bought a new position in Eleven Biotherapeutics during the second quarter valued at $1,670,000. 24.81% of the stock is currently owned by hedge funds and other institutional investors.
Eleven Biotherapeutics Company Profile
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.